Barb73 Posted June 9, 2009 Share Posted June 9, 2009 http://professional.cancerconsultants.c ... x?id=43641 ARTICLE: . . . . . . . . . CancerConsultants.com Zactima™ Shows Promise Against Non–Small Cell Lung Cancer Researchers affiliated with the ZODIAC international Phase III clinical trial have reported that the addition of Zactima™ (vandetanib) to Taxotere® (docetaxel) delayed time to progression among patients with previously treated, advanced non–small cell lung cancer (NSCLC). The details of this study were presented on May 30 at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida. Zactima is a once-daily oral agent targeted against vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), as well as rearranged during transfection (RET) tyrosine kinases. The activity against these three targets makes Zactima a promising new agent. Researchers involved in an international randomized Phase II clinical trial have shown that Zactima™ may be more effective than Iressa® (gefitinib) for second-line therapy of patients with locally advanced or metastatic NSCLC. The details of this study appeared in the May 20, 2009 issue of the Journal of Clinical Oncology. In this study 1,391 patients with advanced NSCLC who had been previously treated with chemotherapy were randomly allocated to receive Taxotere with or without Zactima. Patients have now been followed for roughly one year. The addition of Zactima prolonged time to disease progression from 14 weeks in patients receiving Taxotere to 17.3 weeks. Overall survival did not differ significantly between the two study groups. Patients treated with Zactima experienced an improvement in cancer symptoms. Side effects that were more common among patients treated with Zactima included diarrhea, rash, and low white blood cell counts. Comments: These results suggest that the addition of Zactima to second-line chemotherapy for NSCLC may delay cancer progression and reduce cancer symptoms . . . . . . . . . (CancerConsultants.com, Oncology Resource Center, Information presented May 30 at the 2009 annual meeting of the American Society of Clinical Oncology in Orlando, Florida.) Disclaimer: The information contained in these articles may or may not be in agreement with my own opinions. They are not being posted with the intention of being medical advice of any kind. Quote Link to comment Share on other sites More sharing options...
recce101 Posted June 9, 2009 Share Posted June 9, 2009 There's an article written by one of our members (a patient) posted on cancergrace.org that discusses this and 3 other Zactima clinical trials: http://cancergrace.org/lung/2009/06/08/zactima-by-neil/ Ned Quote Link to comment Share on other sites More sharing options...
Barb73 Posted June 9, 2009 Author Share Posted June 9, 2009 Thank you for the information on that, Ned. It is appreciated. Barbara Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.